Carsten F. Mantel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carsten F. Mantel has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Sandra Mounier-Jack
Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London WC1H 9SH, UK
2 shared publications - Susan A. Wang
World Health Organization, Department of Immunization, Vaccines and Biologicals, Avenue Appia 20, 1211 27, Geneva, Switzerland
2 shared publications - Terri B. Hyde
Global Immunization Division, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA
2 shared publications - David N. Durrheim
School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The University of Newcastle
1 shared publication - Helen Elizabeth Denise Burchett
Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK
1 shared publication - Holly N. Dentz
Department of Nutrition, University of California, Davis, Davis, California
1 shared publication
Latest Publications
- Open Access
- 17 April 2012
- Published by Oxford University Press (OUP) in Health Policy and Planning
- Vol. 27 (suppl 2) , ii1-ii4
The privilege and responsibility of having choices: decision-making for new vaccines in developing countries
Decisions to introduce new vaccines into national immunization programmes have become a highly complex endeavour. When the Expanded Programme on Immunization (EPI) was established in 1974 through a World Health Assembly resolution to build on the success of the global smallpox eradication programme and to ensure that all children in all countries benefit from life-saving vaccines, the first six diseases targeted by EPI were diphtheria, pertussis, tetanus, polio, measles and tuberculosis (WHO 1974). Today, thanks to scientific advancements and renewed global interest in immunization, more than a dozen1 antigens have been made available through public health services in developing countries, with increasingly reduced time delay compared with introduction in industrialized countries. Country decision-makers can select vaccines from a portfolio of options. This is a privilege and a serious responsibility requiring due consideration, as any decision to select one vaccine will need to be taken in light of the opportunity costs of not investing in another vaccine or another (health) intervention. Moreover, country decision-makers do not form their decisions in a vacuum; the number of immunization stakeholders in both the public and the private sectors has vastly increased and those stakeholders are equipped with varying levels of knowledge and expertise and may have vested interests.
- 17 April 2012
- Published by Oxford University Press (OUP) in Health Policy and Planning
- Vol. 27 (suppl 2) , ii1-ii4
Open AccessThe privilege and responsibility of having choices: decision-making for new vaccines in developing countries
Decisions to introduce new vaccines into national immunization programmes have become a highly complex endeavour. When the Expanded Programme on Immunization (EPI) was established in 1974 through a World Health Assembly resolution to build on the success of the global smallpox eradication programme and to ensure that all children in all countries benefit from life-saving vaccines, the first six diseases targeted by EPI were diphtheria, pertussis, tetanus, polio, measles and tuberculosis (WHO 1974). Today, thanks to scientific advancements and renewed global interest in immunization, more than a dozen1 antigens have been made available through public health services in developing countries, with increasingly reduced time delay compared with introduction in industrialized countries. Country decision-makers can select vaccines from a portfolio of options. This is a privilege and a serious responsibility requiring due consideration, as any decision to select one vaccine will need to be taken in light of the opportunity costs of not investing in another vaccine or another (health) intervention. Moreover, country decision-makers do not form their decisions in a vacuum; the number of immunization stakeholders in both the public and the private sectors has vastly increased and those stakeholders are equipped with varying levels of knowledge and expertise and may have vested interests.